Neurocrine Stock Story


USD 107.00  0.24  0.22%   

As many rational traders are trying to avoid healthcare space, it makes sense to break down Neurocrine Bioscienc a little further and understand how it stands against Brickell Biotech and other similar entities. We are going to inspect some of the competitive aspects of both Neurocrine and Brickell.
Published over three months ago
View all stories for Neurocrine Bioscienc | View All Stories

Will Neurocrine Bioscienc (NASDAQ:NBIX) investors shift to Brickell (NASDAQ:BBI)?

By analyzing existing forward indicators between Neurocrine Bioscienc and Brickell, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Brickell with a short position in Neurocrine Bioscienc. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Neurocrine Bioscienc has an asset utilization ratio of 225.37 percent. This suggests that the company is making $2.25 for each dollar of assets. An increasing asset utilization means that Neurocrine Bioscienc is more efficient with each dollar of assets it utilizes for everyday operations.

How important is Neurocrine Bioscienc's Liquidity

Neurocrine Bioscienc financial leverage refers to using borrowed capital as a funding source to finance Neurocrine Bioscienc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Neurocrine Bioscienc financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Neurocrine Bioscienc's total debt and its cash.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Neurocrine Bioscienc, but it might be worth checking our own buy vs. sell analysis

Exercise or conversion by Malcolm LloydSmith of 1227 shares of Neurocrine Bioscienc subject to Rule 16b-3

Legal trades by Neurocrine Bioscienc insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Neurocrine insider trading alert for exercise of incentive stock option by Malcolm LloydSmith, Chief Regulatory Officer, on 16th of August 2022. This event was filed by Neurocrine Biosciences In with SEC on 2022-08-16. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down the case for Neurocrine Bioscienc

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Let me now analyze Neurocrine Bioscienc revenue. Based on the latest financial disclosure, Neurocrine Bioscienc reported 1.07 B of revenue. This is 85.97% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The revenue for all United States stocks is 88.66% higher than that of Neurocrine Bioscienc. As for Brickell Biotech we see revenue of 327 K, which is much higher than that of the Drug Manufacturers—Specialty & Generic

1.1 B
NBIX1.07 Billion99.97

Neurocrine Bioscienc is epected to finish above $87 in June

The maximum drawdown is down to 12.07 as of today. Neurocrine Bioscienc has relatively low volatility with skewness of 0.56 and kurtosis of 3.47. However, we advise all investors to independently investigate Neurocrine Bioscienc to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Neurocrine Bioscienc's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Neurocrine Bioscienc's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Neurocrine Bioscienc Implied Volatility

Neurocrine Bioscienc's implied volatility exposes the market's sentiment of Neurocrine Bioscienc stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Neurocrine Bioscienc's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Neurocrine Bioscienc stock will not fluctuate a lot when Neurocrine Bioscienc's options are near their expiration.

Our Final Perspective on Neurocrine Bioscienc

While other companies in the drug manufacturers—specialty & generic industry are either recovering or due for a correction, Neurocrine Bioscienc may not be performing as strong as the other in terms of long-term growth potentials. With a relatively neutral outlook on the current economy, it is better to hold off any trading of Neurocrine as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Neurocrine Bioscienc.

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Neurocrine Bioscienc. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to